Prof. Dr. med. David Capper

Molecular Neuropathology
Institute of Neuropathology
Charité - Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin
Tel: +49 30 450 536 940
Fax: +49 30 450 536 498

E-Mail: david.capper(at)charite.de
https://neuropathologie.charite.de/en/research/molecular_neuropathology/

Scientific Scope

The research group "Molecular Neuropathology" works on the analysis of molecular changes in brain tumors and other tumor diseases. A special focus is on epigenetic alterations and the application of these changes for tumor classification.

Future Directions

The aims of this research group include: expanding the molecular characterization of brain tumors, the identification of oncogenic drivers in rare brain tumors, investigating the mechanisms underlying tumor development, developing machine learning based approaches for brain tumor classification and the translational application of new diagnostic tools.

Group Members

David Capper - Associate Professor for Molecular Neuropathology
Daniel Teichmann – Technical Assistant
Stefanie Glöß – Medical student
Simone Schmid – Resident
Benjamin Englert - Resident
Christin Siewert – Bioinformatician
Anne Schöler – Bioinformatician
Eilís Perez – PhD Student

Most important Awards, Grants or Scientific Achievements

  • 2018     Curt Meyer Memorial award of the Berliner Krebsgesellschaft (10.000€)
  • 2018     Berlin Institute of Health (BIH) Quest open data award (1.000€)
  • 2018     Innovation prize of the Deutschen Hochschulmedizin e.V. (10.000€)
  • cIMPACT: the consortium to inform molecular and practical approaches to CNS tumortaxonomy member.
  • Member of the “Consensus and Editorial Meeting Working Group” for the Update of the 4th edition of the WHO Classification of Tumours of the Central Nervous System.
  • Member of the German Society for Neuropathology and Neuroanatomy (DGNN)
  • Member of the Society for Neuro-Oncology

Selected References

  • Capper D, Jones DTW, Sill M, Hovestadt V et al., DNA methylation-based classification of central nervous system tumours. Nature. 2018 Mar 22;555(7697):469-474.
  • Reinhardt A, …. Capper D. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol. 2018 Mar 21.
  • Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A: Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody, Acta Neuropathol. 2011 Jul;122(1):11-9. doi: 10.1007/s00401-011-0841-z.
  • Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A: Monoclonal antibody specific for IDH1 R132H mutation, Acta Neuropathol 2009, 118:599-601.
  • Schindler G*, Capper D*, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A: Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma, Acta Neuropathol 2011, 121:397-405.